New hope for kids with hemophilia: can SCT800 stop bleeds before they start?
NCT ID NCT07437404
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing a drug called SCT800, a lab-made clotting factor, to prevent bleeding episodes in 36 boys with severe hemophilia A who have never been treated before. Participants receive regular infusions of SCT800, and researchers will monitor how many bleeding events occur and whether the body develops antibodies that could block the treatment. The goal is to see if this approach is safe and effective for long-term prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SCT800 (a recombinant factor VIII replacement therapy)
- What this could lead to
- If successful, this could provide a safe and effective preventive treatment option for children with severe hemophilia A who have not yet received any factor VIII therapy.
- What could go wrong
- This is a small, open-label study with no control group, so results may be less reliable. There is a risk of developing inhibitors (antibodies) that block the treatment's effect, a known complication in previously untreated patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing children's hospital
RECRUITINGBeijing, Beijing Municipality, 000000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Can an ultra-long-acting factor VIII simplify surgery for hemophilia a patients?
- New clotting factor aims to cut bleeding episodes in severe hemophilia a
- New clotting factor aims to stop bleeding in severe hemophilia a
- Patient voices take center stage in haemophilia a treatment decisions